Lara Green

Lara Green

@laragreen.bsky.social

Research manager at Breakthrough T1D Canada (formerly JDRF), PhD in neurophys, mom of 2 little boys, jigsaw puzzle enthusiast, enjoyer of wine and food!

165 followers94 following56 posts

Lara Green
@laragreen.bsky.social

SCN is launching the second of two national research funding competitions and Breakthrough T1D is excited to partner again on joint-funding award opportunities!    Webinar: August 13, 2026, at 1pm ET Competition opens August 31, 2026. More details here: tinyurl.com/SCN-FO

tinyurl.comResearch Funding - Stem Cell NetworkFor more than 20 years, the Stem Cell Network has made strategic investments in stem cell and regenerative medicine research, helping to position Canada as a global leader in the field. As Canada’s on...
Lara Green
@laragreen.bsky.social

This proposal was shaped with input from researchers, clinicians, industry experts, policymakers, and members of the T1D community, all focused on one shared goal: ensuring people in Canada can benefit from breakthrough therapies as soon as possible.

Lara Green
@laragreen.bsky.social

The BTNC is designed to: • Link expertise, ideas, and efforts across the country • Bring T1D clinical trials to Canada faster • Support more trial sites nationwide • Help ensure therapies are developed, tested, and delivered in Canada

Lara Green
@laragreen.bsky.social

Calling all residents and fellows interested in type 1 diabetes #T1D research! Breakthrough T1D Canada's Clinician Investigator Fellowship is currently open for applications. Up to $50,000 salary support per year. Deadline to submit is March 31st. breakthrought1d.ca/research/gra...

breakthrought1d.caBreakthrough T1D Canada Clinician Investigator Fellowship Program  | Breakthrough T1DJDRF Clinician Investigator Fellowships are designed to attract and promote clinician scientists in the field of T1D research. These fellowships are open to medical residents who are pursuing graduate...
Lara Green
@laragreen.bsky.social

Last week, Breakthrough T1D Canada had the privilege of co-hosting a workshop with Canada’s Stem Cell Network and Shift Health focused on a critical and complex topic:  "Unlocking Access for Type 1 Diabetes Cell Therapies in Canada: Identifying Solutions for Regulatory and Reimbursement Success."

Lara Green
@laragreen.bsky.social

Key themes that emerged: ✅ The value of cell therapies - both clinical outcomes AND what matters to people living with T1D ✅ The need for regulatory clarity for cell therapies ✅ Capitalizing on opportunities to collaborate ✅ How innovative models can enable reimbursement of cell therapies in Canada

Lara Green
@laragreen.bsky.social

The workshop brought together regulators, payers, legal experts, researchers, industry experts, non-profit leaders and people with lived experience. Let’s keep the conversation going. If you’re working in this space or have ideas - please connect!!

Lara Green
@laragreen.bsky.social

‘Official’ results from the Vertex VX-880 trial using stem cell-derived islets for people with type 1 diabetes #T1D 10 out of 12 people with reduced or eliminated need for insulin 🎉 But note the need for immunosuppression and limited eligibility… this is not (YET) the ‘cure for everyone’

nejm.orgStem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJMZimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimisle...
Lara Green
@laragreen.bsky.social

Excellent to see this Breakthrough T1D and CIHR-funded research by Dr. Mahmud at SickKids (Toronto) that shows improved glycemic control and kidney function when using the drug dapagliflozin in youth. Exciting to see research progress toward adjunctive therapies for #T1D.

temertymedicine.utoronto.caClinical trial shows improved health outcomes for teens with type 1 diabetesA clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney disease and improve health outcomes. The findings could help guide more prec...
Lara Green
@laragreen.bsky.social

📣 Calling all trainees and early-career researchers studying type 1 diabetes #T1D Breakthrough T1D has postdoctoral fellowships and early careers awards for academics and clinician-scientists. 🗓️ Proposals due July 1 International applicants welcome! www.breakthrought1d.org/explore-rese...

breakthrought1d.orgType 1 Diabetes Funding Opportunities - Breakthrough T1DExplore Breakthrough T1D’s funding opportunities for type 1 diabetes research. Learn how we support innovative projects driving breakthroughs in T1D treatment, prevention, and cures.
Lara Green
@laragreen.bsky.social

What a legacy 🇨🇦 Drs. Till & McCulloch discovered stem cells in the 60s which changed the future of regenerative medicine and contributed to solving one of the biggest hurdles (having enough cells) in the quest to cure type 1 diabetes #T1D #stemcell

Stem Cell Network@stemcellnetwork.ca

(1/3) It is with profound sadness that we honour the passing of Dr. James Till, a pioneering Canadian scientist whose work, alongside Dr. Ernest McCulloch, laid the very foundation of stem cell research. stemcellnetwork.ca/celebrating-...

Lara Green
@laragreen.bsky.social

A short (12-min) interview about the current and future of islet transplantation. Worth a listen for anyone interested in learning more about cures for #T1D

European Association for the Study of Diabetes@easdnews.bsky.social

🎙️The future of #T1D care: Are we closing in on a cell-based cure? From islet transplants to stem cell-derived therapies, experts Dr James Shaw, Dr Timothy Kieffer & Dr Trevor Reichman explore the cutting edge of regenerative diabetes treatment. 🎧Listen now 👉 www.easd.org/media-centre...

Lara Green
@laragreen.bsky.social

The approval of Tzield makes screening even more important for Canadians. How will we find people who are early-stage #T1D that don’t yet have signs and symptoms but have an autoimmune attack silently killing beta cells. Our approach is real-world evidence generation via www.canscreent1d.ca

canscreent1d.caHome - CanScreen T1D Research ConsortiumThe Canadian Population Screening for Risk of Type 1 Diabetes (CanScreen T1D) research consortium aims to launch a pilot screening program for children in Canada. The consortium studies the accessibility and feasibility of a T1D screening program through different research projects, ensuring equity, diversity, and inclusion measures in the program design.

Lara Green reposted

Alan Chiu
@chiuonscience.bsky.social

Several BreakthroughT1D funding opportunities available 1) Advancing GRS, especially in non-European backgrounds 2) Early detection in adult-onset T1D 3) Tech for scaling manufactured islets Feel free to reach out with questions. Open to industry and academia #funding #grants #T1D

breakthrought1d.orgType 1 Diabetes Funding Opportunities - Breakthrough T1DExplore Breakthrough T1D’s funding opportunities for type 1 diabetes research. Learn how we support innovative projects driving breakthroughs in T1D treatment, prevention, and cures.
Lara Green
@laragreen.bsky.social

Beyond the Numbers: Real Stories of Navigating Mental Health with type 1 diabetes #T1D. This powerful new video series shares the honest, emotional stories of adults living with type 1 diabetes. 💙 🔗 Watch the series ow.ly/aqb950VKwkL 🔗 Explore mental health & T1D resources ow.ly/J49v50VKwkK

ow.lyBeyond the Numbers: Real Stories of Navigating Mental Health with T1D | Au-delà des chiffres : De vraies histoires sur la santé mentale avec le DT1 - YouTube
Lara Green
@laragreen.bsky.social

Great new research - one of the difficult aspects of #T1D is that there’s no way to “see” islet or beta cells to check if they are being attacked or functioning well so new biomarkers are important! (More info in comments…)

STOP T1D@stopt1d.bsky.social

#T1D Research Report Findings: "M120 identified 26% more children at high risk of progression" of #Type1Diabetes. "M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-Term Response to Preventive Immunotherapy" bit.ly/4jwYfGL

bit.lyM120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-Term Response to Preventive ImmunotherapyOBJECTIVE. Approval of teplizumab as disease-modifying therapy for type 1 diabetes heralds a new therapeutic era. To facilitate prevention trials, we deter
Lara Green
@laragreen.bsky.social

A biomarker is something measurable that indicates what’s happening in the body (an A1c is a biomarker of blood glucose). With an increase in screening tests and preventative therapies, biomarkers of beta cell function are becoming more important.

Lara Green
@laragreen.bsky.social

When beta cells make insulin, C-peptide is ‘broken off’ and this can be measured in blood draws. C-peptide has been the ‘primary outcome’ for many #T1D preventative therapy trials, but it’s not a very sensitive test and can be costly.

Lara Green
@laragreen.bsky.social

So much knowledge comes from a registry - this is a catalyst for many other research projects and often helps guide research priorities! If you (or your child) lives with type 1 diabetes #T1D #LADA and are located in Canada 🇨🇦, PLEASE consider contributing to research! (Completely virtual too).

Type 1 BETTER@type1better.bsky.social

🎉 5,000 people have joined the BETTER registry! 🎉 Thanks to you, research is moving forward and we’re improving our understanding of the realities faced by people living with type 1 diabetes and LADA in Canada. #type1diabetes #BETTERregistry #diabetesresearch #T1D #LADA #Canada #PatientVoices

type1better.comThe BETTER registry reaches 5,000 participants – BETTERWe’re excited to share a major milestone for the BETTER project: more than 5,000 people living with type 1 diabetes (T1D) or latent autoimmune diabetes in adults (LADA) in Canada have joined the BETTE...
Lara Green
@laragreen.bsky.social

VERY important research from the fantastic Dr. Jane Speight. The burden of self-managed chronic conditions should not be underestimated! If you live in Canada and want to find a mental health worker that understands diabetes burden ( #T1D or #T2D) - check on our directory.breakthrought1d.ca

directory.breakthrought1d.caHome - Mental Health Diabetes DirectoryCosts & Coverage Please note that most mental health providers typically charge a fee on a per visit basis. If you have private insurance, it may cover specific mental health services. We recommend ch...
European Association for the Study of Diabetes@easdnews.bsky.social

❓What is the psychosocial impact of living with #diabetes? 🔎In our new Gamechangers episode, Prof. Jane Speight spotlights a paper that, for the first time, outlined the concept of #diabetesdistress. 📺Watch here: easd-elearning.eu/index.html@p... #elearning

Lara Green
@laragreen.bsky.social

Unfortunate to see today’s news from Vertex about their VX-264 therapy for #T1D but this is why we always have ‘multiple shots on goal’! Considering that the same cells are being used as in VX-880 (so far great data) it’s reasonable to assume that the device encapsulation was the problem here.

Lara Green
@laragreen.bsky.social

For those curious why the same cells are effective on one trial (VX-880) and not another (VX-264)… The 880 trial is putting the cells directly into the body and using immunosuppression drugs to protect them. The 264 trial was putting the same cells in a ‘teabag’ device that goes under the skin

Lara Green
@laragreen.bsky.social

Always exciting to see new Clinical Practice Guidelines, but these are especially exciting: - T1D across the lifetime instead of broken up into stages 👏 - recommending AID for all ages and stages of T1D 👏👏 - first in the world to recommend considering the use of adjunctive therapies for T1D 👏👏👏

Lara Green
@laragreen.bsky.social

Really fascinating debate at #ATTD2025 about whether or not we should use placebos in trial design for preventative therapies of #T1D now that Tzield (teplizumab) has shown efficacy and is approved in a few countries. Heavy hitters Colin Dayan and Laura Jacobsen presented excellent points!

Lara Green
@laragreen.bsky.social

Take-home message: we need better trial design for preventative therapies... adaptive trial design is likely the best option, but #T1D is such a heterogenous disease and finding people in early-stage is difficult!

Lara Green
@laragreen.bsky.social

This is so powerful… “Has your diabetes been impacted by menopause?” 88% say YES! Research is starting to grow in this area: to see Canadian trials related to menopause and #T1D check out our Clinical Trial Finder clinicaltrials.breakthrought1d.ca

clinicaltrials.breakthrought1d.caBreakthrough T1D - Clinical Trials
Dawnie@moodwife.bsky.social

The #T1D and #Menopause poster has gone live at #ATTD2025 🥳 Thanks to #dedoc° for making it possible for so many of us who were involved to attend

Lara Green
@laragreen.bsky.social

Thrilled to (virtually) watch a fantastic talk at #ATTD2025 from Dr. Cristina Nostro about co-culturing pluripotent stem cells with macrophages which not only provides protection but also increases endocrine output!

Lara Green
@laragreen.bsky.social

📣Students and postdocs, consider Canadian universities for grad studies! Tuition is typically offset by teaching assistantships for seminars/labs, and applying is as simple as making contact with a PI to start. If you’re in the field of #T1D - reach out if you’d like us to help make a connection!

Francis Lynn 🇨🇦@nictitate.bsky.social

It’s pretty easy to “apply” for a PhD in Canada, and a little different from most US places, just send a cover letter, CV and undergrad transcript to a PI you’d like to work with. Put some effort into it, make sure you convey what you’re applying for and why.

Lara Green
@laragreen.bsky.social

Registries are such a critical accelerator for research! If you or someone you know in Canada lives with #T1D, please consider being a part of the BETTER Registry!

Type 1 BETTER@type1better.bsky.social

🔬 A study is currently underway using data from the BETTER registry to explore other autoimmune diseases in type 1 diabetes and the associated risks. 💙 Join the registry now if you (or your child) live with type 1 diabetes or LADA in Canada 🇨🇦 🔗 type1better.com/en/the-bette... #T1D #research

Lara Green reposted

Francis Lynn 🇨🇦
@nictitate.bsky.social

I have funding through at least 2031 for postdoctoral researchers with expertise in islet biology or cell-based therapies for, or modelling of, diabetes. Bring your expertise to a country that values it. 🇨🇦 Contact info on my website.

Lara Green
@laragreen.bsky.social

Excellent opportunity for a postdoctoral fellow to join the Breakthrough T1D Centre of Excellence at UBC. International applicants welcome!!!

Stem Cell Network@stemcellnetwork.ca

Are you applying for the J. Andrew McKee Fellowship in Type 1 Diabetes?    Supported by SCN and Breakthrough T1D (formerly JDRF), this is your chance to join UBC’s Breakthrough T1D Centre of Excellence. Submit your application by February 27, 2025. ➡️ stemcellnetwork.ca/training/exc...

Lara Green
@laragreen.bsky.social

Early-detection for #T1D is ramping up globally and we have seen the first systemwide (non-research) mandate from Italy for genpop type 1 diabetes screening. To find out what is happening in Canada, check out canscreent1d.ca -> a $12M research consortium funded by Breakthrough T1D and CIHR INMD.

canscreent1d.caHomeCanScreen T1D Research Consortium Creating Canada's First Type 1 Diabetes Screening Program Learn about what we do CanScreen T1D Research Consortium Your child’s health matters. The Canadi...

Lara Green reposted

DREAM Theme
@dreamdiabetes.bsky.social

Replying to @dreamdiabetes.bsky.social

8/ DREAM researcher Dr. Peter Thompson and his lab revealed that #GDF15 is crucial for regulating gene expression during beta cell senescence in #Type1Diabetes, but not for cell survival. Could it be a target for T1D therapies? #BetaCellResearch #CellSenescence pubmed.ncbi.nlm.nih.gov/39196800/

pubmed.ncbi.nlm.nih.govSecreted GDF15 maintains transcriptional responses during DNA damage-mediated senescence in human beta cells - PubMedType 1 diabetes (T1D) is a chronic metabolic disease resulting from an autoimmune destruction of pancreatic beta cells. Beta cells activate various stress responses during the development of T1D, incl...
Lara Green
@laragreen.bsky.social

Looking forward to reading this! It’s always great to see open-science supporting other researchers too!

Anna Gloyn@annagloyn.bsky.social

Want to generate #T1DGRS in your data or data from any biobank? @SethASharp has updated his #GRS2 originally developed with Richard alarm & Mike Weedon - code available on #GitHub Great collaboration with AmberMLuckett medrxiv.org/content/10.110… github.com/sethsh7/prsedm 👇👇👇

Lara Green
@laragreen.bsky.social

Great to see this high impact publication on the use of Semaglutide (Ozempic) in #T1D from a fantastic group of researchers in Montreal. www.nature.com/articles/s41...

nature.comSubcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial - Nature MedicineIn a crossover trial evaluating semaglutide versus placebo as an add-on to automated insulin delivery therapy in adults with type 1 diabetes, the use of semaglutide was associated with an increased pe...